Eptifibatide

依替巴肽

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameEptifibatide
Drug Alias Nameeptifibatidum埃菲替巴肽eptifibatida埃替非巴肽Intrifiban +[12] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionIntegrin alpha-IIb/beta-3 antagonists
TargetsIntegrin alpha-IIb/beta-3
Therapy Area/IndicationsIschemic StrokeAnemia, Sickle CellST Elevation Myocardial Infarction +[6] 
Global Approved IndicationsMyocardial InfarctionAngina, UnstableAcute Coronary Syndrome
Approved Indications in ChinaMyocardial InfarctionAngina, Unstable
Original Approved Country/TerritoryUnited States
Original Approved Date1998/05/18
Country/TerritoryCanadaUnited StatesGermany +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMillennium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Second Affiliated Hospital of Army Medical UniversityJiangsu Hansoh Pharmaceutical Group Co LtdNanjing Changao Pharmaceutical Science And Technologyco Ltd +[5] 
Inactive CompaniesThe Brigham and Women's HospitalGlaxosmithkline PlcGlaxosmithkline (Ireland) Ltd +[8] 
Active IndicationsIschemic StrokeMyocardial InfarctionAngina, Unstable +[4] 
Inactive IndicationsAnemia, Sickle CellST Elevation Myocardial Infarction

Other Information

ATC CodeB01AC16
Related LinksWikipediaDrugBankKEGG